Smith & Nephew reported largely in line Q2 numbers – on both the top-line as well as the bottomline. The performance of the sports medicine joint repair, other surgical devices, knee implants and advanced wound devices segments were the key positives, while advanced wound bioactives, arthroscopic enabling technologies and trauma businesses posted sales declines. We do not expect any significant changes to our estimates/recommendation.
04 Aug 2018
In line results as new CEO takes charge
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line results as new CEO takes charge
Smith & Nephew plc (SN:LON) | 973 120.7 1.3% | Mkt Cap: 8,507m
- Published:
04 Aug 2018 -
Author:
Kamla Singh -
Pages:
3
Smith & Nephew reported largely in line Q2 numbers – on both the top-line as well as the bottomline. The performance of the sports medicine joint repair, other surgical devices, knee implants and advanced wound devices segments were the key positives, while advanced wound bioactives, arthroscopic enabling technologies and trauma businesses posted sales declines. We do not expect any significant changes to our estimates/recommendation.